Immunovia
Business Services · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Scheelevägen Medicon Village 2, Lund, Sk...Phone Number
+46 462756000Website
www.immunovia.comRevenue
$14.4 MillionStock Symbol
IMMNOVIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer based on Immunovia's proprietary test platform called IMMray. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature". The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancerRead more
Immunovia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunovia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Immunovia is spiking on competitors!
Immunovia, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Immunovia launches new products
Click to see if Immunovia had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Immunovia
Check if Immunovia has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Immunovia recently announced quarterly report
Funding: Get notified immidiatlly once Immunovia has new funding data
Recommended Actions
Reach out to Masked Content who joined Immunovia as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Immunovia is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immunovia is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immunovia.
Immunovia financials insights
Gather financial insights about Immunovia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$43M
Immunovia Tech Stack
A closer look at the technologies used by Immunovia
Most Recent Scoops
Earnings
Immunovia has reported that its sales pipeline for the PancreaSure test grew from 32 prospects at the end of December 2025 to 71 prospects at the end of March 2026, representing a 145% increase, driven by the onboarding of three strategic account managers hired in January and February 2026.
CRM, Hiring Plans, Sales, Account Management
Earnings
Immunovia has identified a current total addressable market of approximately $540 million (nearly SEK 5 billion) based on approximately 600,000 high-risk individuals in the US, with a potential expanded market of approximately $1.5 billion (SEK 13.8 billion) for approximately 1.7 million AI-identified high-risk individuals, based on an assumed value of $900 per person for the PancreaSure test.
Project
Immunovia has announced that billing of insurance companies for the PancreaSure test began in February 2026, with a Medicare coverage submission planned for Q3 2026, while work with commercial payers is already underway and will continue through 2026 and into 2027.
Accounting, Billing & Invoice, Finance
Project
Immunovia has announced that analytical validity and clinical validity data for the PancreaSure test have been developed and published in peer-reviewed publications, with work on clinical utility now underway to support payer coverage submissions.
Medical Research, Clinical Operations
Project
Artificial Intelligence
Immunovia News & Media
Immunovia AB (IMMVF) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges and ...
Immunovia AB (IMMVF) outlines its strategic initiatives and financial hurdles as it advances the PancreaSure test and seeks broader market penetration.Immunovia AB (publ) (IMMVF) Q3 2025 Earnings Call Transcript
Immunovia AB (publ) (OTC:IMMVF) Q3 2025 Earnings Call November 26, 2025 9:00 AM ESTCompany ParticipantsJeff Borcherding - Global Chief Executive Officer...Immunovia Secures SEK 100 Million for PancreaSure Launch - TipRanks.com
An announcement from Immunovia AB ( ($SE:IMMNOV) ) is now available. Immunovia AB successfully completed a rights issue, raising approximately SEK 100 million to su...Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG (“Proteomedix”) has signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunovia
Sign Up For FreeTo access detailed company insights
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer based on Immunovia's proprietary test platform called IMMray. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarker... Read More
